ArticleNature reviews. Methods primers2023
Nanotechnology-based mRNA vaccines.
Article in Nature reviews. Methods primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- miR-34a and miR-223 as diagnostic biomarkers for the severity of non-alcoholic fatty liver disease.Journal, genetic engineering & biotechnology · 2026Article
- Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics.Science advances · 2026Article
- Highly Biomimetic Ectodermal Epithelial Organoids for Epithelial Barrier Stimulation Assays.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development of a Lensless Compact Optical System for Ultrasensitive Nanomaterial Detection in Liquid Media via Exploiting Multiple Light Scattering.Nanophotonics (Berlin, Germany) · 2026Article
- Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy.Molecular therapy. Nucleic acids · 2026Review
- The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.Drug delivery and translational research · 2026Article
- More than just a delivery system.Nature reviews. Chemistry · 2026Article
- mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026Review
- Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma.Molecular therapy. Nucleic acids · 2026Article
- Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy.Nature nanotechnology · 2026Article
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Fragment to framework: automatic fragmentation of covalent organic frameworks into building blocks for band gap analysis.Materials chemistry frontiers · 2026Article
- Smart dendrimer nanogels boost mRNA-based cancer therapy via synergistic glycolysis inhibition and immune activation.Bioactive materials · 2026Article
- A Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The global threat of vaccine-preventable neurological diseases.Nature reviews. Neurology · 2026Review
- CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors.Journal for immunotherapy of cancer · 2026Article
- Tissue-specific mRNA delivery and prime editing with peptide-ionizable lipid nanoparticles.Nature materials · 2026Article
- A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies.Cureus · 2026Review
- Review
- Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy.Journal of translational medicine · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
mRNA vaccines have emerged as a revolutionary tool to generate rapid and precise immune responses against infectious diseases and cancers. Compared with conventional vaccines such as inactivated viruses, viral vectors, protein subunits or DNA-based vaccines, mRNA vaccines stand out owing to multiple advantages, including simplicity of design, fast production, enhanced safety and high efficacy. Nevertheless, efficient and targeted delivery of mRNA molecules remains a significant challenge owing to their inherent instability and susceptibility to degradation. Nanotechnology offers innovative solutions to surmount these obstacles and amplify the potency of mRNA vaccines. This Primer aims to outline a modular approach to developing biomaterials and nanotechnology for mRNA vaccines, with a focus on particle design, formulation evaluation and therapeutic applications. We delve into the underlying mechanisms of nanoparticle-facilitated mRNA protection, cellular uptake, endosomal escape and immune stimulation. We underscore the critical parameters that impact the manufacturing and clinical implementation of nanomaterial-based mRNA vaccines. Finally, we present the current limitations and future perspectives in the advancement of nanotechnology-enhanced mRNA vaccines for broad applications in prophylactic and therapeutic interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.